• About us
• Contact

Advertisement

Person › Details

Laszlo Radvanyi (Merck KGaA)

Radvanyi, Laszlo (Merck (DE) 201511– Head of Global Immuno-oncology Research before CSO at Lion Biotechnologies)

 

	Organisation	Merck KGaA
	Group	Merck (DE) (Group)
	Product	cancer immunotherapy (immuno-oncology, I-O)
	Product 2	oncology

Record changed: 2017-04-09

Advertisement

More documents for Laszlo Radvanyi

• [1] Merck KGaA. (1/23/17). "Press Release: Merck Announces Research Collaboration with Domain Therapeutics in Immuno-Oncology [Not intended for UK- or US-based media]". Darmstadt....
• [2] Domain Therapeutics S.A.. (1/23/17). "Press Release: Domain Therapeutics and Merck Enter into a License and Collaboration Agreement for Development of Adenosine Receptor Antagonists in Immuno-oncology". Strasbourg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.